Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 11/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662041 | 0.88 | S1PR1 (0.49) | S1PR1S1PR3KDM4ELMNANFKB1 | |
| SCHEMBL1661378 | 0.87 | S1PR1 (0.49) | S1PR1S1PR3KDM4ELMNANFKB1 | |
| SCHEMBL1663946 | 0.86 | S1PR1 (0.40) | S1PR1S1PR3DRD3 | |
| SCHEMBL1661947 | 0.84 | S1PR1 (0.38) | S1PR1S1PR3DRD3 | |
| SCHEMBL1661932 | 0.84 | S1PR1 (0.41) | S1PR1S1PR3 | |
| SCHEMBL1661351 | 0.81 | S1PR1 (0.61) | S1PR1S1PR3KDM4ELMNANFKB1 | |
| SCHEMBL1661803 | 0.81 | SMN1; SMN2 (0.46) | S1PR1S1PR3KDM4ELMNASMN1; SMN2 | |
| SCHEMBL1662511 | 0.80 | APP (0.41) | S1PR1S1PR3SMN1; SMN2 | |
| SCHEMBL1661746 | 0.79 | S1PR1 (0.56) | S1PR1S1PR3 | |
| SCHEMBL17801761 | 0.79 | NPC1 (0.48) | S1PR1S1PR3KDM4ENFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2306994-B1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-2306994-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | Amgen, Inc (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7842685-B2 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009154775-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR3 4/4885KDM4E 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.